In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.
about
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium RetentionPrioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput DataIdentification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazoneDoes combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy?Association of Exposure to Di-2-Ethylhexylphthalate Replacements With Increased Insulin Resistance in Adolescents From NHANES 2009-2012.Protective Role for Tissue Inhibitor of Metalloproteinase-4, a Novel Peroxisome Proliferator-Activated Receptor-γ Target Gene, in Smooth Muscle in Deoxycorticosterone Acetate-Salt Hypertension.Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.What are the pharmacotherapy options for treating prediabetes?Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes.Metabolic Flexibility in Health and Disease.The EMPA-REG study: What has it told us? A diabetologist's perspectiveMutual induction of transcription factor PPARγ and microRNAs miR-145 and miR-329.Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight.The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes.Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-α pathway.The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 InhibitionType 2 diabetes mellitus
P2860
Q26851905-AF787E33-E6D8-4B96-82D8-B59F57DAA55CQ28831114-F93B20CC-5B9E-464C-9780-E68191099254Q34511474-3C287C1D-03B5-4F73-B18C-82B1EE1A95C3Q35183612-3C5BE0A7-B4E7-4992-A029-E6A7F821C384Q35813271-DAA6DC9F-167A-4319-AD17-FD6203F441CEQ36372517-5FFC324B-8BCC-4639-8E03-18D09CB2D01FQ36742028-0CFC68BB-AE0B-4991-8079-E05256D54802Q37577162-2C1667A5-2B0C-4926-A017-43F2C8EE435CQ38241464-FDED18AE-1C32-435D-955C-BECDFE0F2534Q38318147-0A371C3B-5AB5-45A2-8590-D7F3A6A468F7Q38524435-83718A03-D788-441B-A68C-2A4D11F766CDQ38725752-2888D027-47B3-468D-BA86-A50391DF6AFDQ39280816-BE53CD3E-3519-4BD9-8665-C4AC741EB679Q41147002-AE331102-35DE-4BE2-8F6C-4F42E53B26CCQ42738912-35DFC1CE-338A-448C-9395-4AD10E2EEAFBQ47173290-4A1C5B45-36D9-4420-9BC7-6950E09D7A79Q47261527-33BD7AA4-C23C-492A-986C-AA44A5B608F3Q47785505-A4AE2DE1-9D48-4C03-A33F-D38659B0BEABQ47849041-A65A3FDC-17C1-4EDE-A786-6C0A60846FB7Q55195472-44E92F88-295B-42D8-94B3-3806C8B3E86BQ55285122-8690804B-F1A7-47BC-AC79-565169507196Q57300008-5E34112F-F440-4C72-9C41-24EBD9055C93Q58447602-703538F8-F265-49CD-B10B-695B1642572A
P2860
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@en
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@nl
type
label
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@en
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@nl
prefLabel
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@en
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@nl
P2860
P921
P356
P1433
P1476
In vivo actions of peroxisome ...... tivity, and insulin secretion.
@en
P2093
Muhammad Abdul-Ghani
P2860
P304
P356
10.2337/DCS13-2003
P407
P478
36 Suppl 2
P577
2013-08-01T00:00:00Z